Dovitinib lactate is a multi-targeted tyrosine kinase inhibitor primarily used in the treatment of various types of cancers, particularly those involving FGFR (Fibroblast Growth Factor Receptor) mutations, such as renal cell carcinoma, and gastrointestinal stromal tumors resistant to other therapies. It functions by inhibiting multiple kinases involved in cell signaling pathways, which helps in blocking the growth and spread of cancer cells. This makes it effective in slowing down tumor progression and improving patient outcomes. Additionally, it is being researched for its potential in treating other cancers, including breast, lung, and pancreatic cancer, due to its ability to target multiple pathways involved in cancer cell proliferation and survival.